Mobic Labeling Revision Includes Class Risk Language
This article was originally published in The Pink Sheet Daily
Executive Summary
Boehringer Ingelheim’s addition of cardiovascular and gastrointestinal risk information to Mobic labeling coincides with FDA approval of a juvenile rheumatoid arthritis indication for meloxicam.